Sutro Biopharma, Inc

ABOUT

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
  • 2025 BPTW Badge - RBG.png
111 Oyster Point Blvd
South San Francisco, CA 94080
Stock Symbol: STRO
  • Featured Employer Badge
Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV
LEADERSHIP TEAM
  • William J. Newell, J.D.
    Chief Executive Officer
  • Edward Albini, M.B.A.
    Chief Financial Officer
  • Anne Borgman, M.D
    Chief Medical Officer
  • Jane Chung, R.Ph.
    President & Chief Operating Officer
  • Linda Fitzpatrick
    Chief People & Communications Officer
  • Hans-Peter Gerber, Ph.D.
    Chief Scientific Officer
  • Barbara Leyman, Ph.D.
    Chief Business Development Officer
  • David Pauling, J.D., M.A.
    General Counsel
  • Venkatesh Srinivasan, Ph.D.
    Chief Technical Operations Officer
THE WAY WE WORK

At Sutro, our collaboration drives how we achieve results. By putting the goals of Sutro first, we aim to make a difference in the lives of patients. We strive to make a difference as individuals and as part of a team.

OUR PRINCIPLES:

  • Collaboration and Execution
  • Respect and Engage
  • Integrity and Dependability
  • Diversity, Equity, Inclusion and Belonging


Diversity matters. We strive to create an environment in which each Sutroite is respected and valued. We are a team that embraces members from all races, ethnicities, nationalities, gender-identities, ages, sexual orientations, abilities and disabilities. We are aligned by a single, shared purpose; to bring life-saving and life-extending medicines to cancer patients. We know each day matters to them. We are relentless in our pursuit; success is dependent on contributions from every member of our team.

We do our best to listen and learn from one another. We build upon the ideas of each other; this makes each of us better and is critical to success. We are on an important mission, and we give our absolute best to our colleagues and to our work, every day.

We value our differences and fundamentally believe our differences strengthen us. We strive to treat everyone with respect and with fairness. We think beyond what’s important to us; we include others and different points of view. As a Sutroite you belong – to our purpose, to each other, and to our community.

Investing in a sustainable future for generations to come


As part of our commitment, Sutro Biopharma manages our internal operations in ways that are both socially and ecologically responsible. We constantly search for new innovations that will help our operations and our teams minimize environmental footprint and sustain healthy communities.

RECOGNITIONS AT-A-GLANCE

  • Zero Waste Strategy
  • Medical Waste-To-Energy
  • Recycling of Chemical Hazardous Wastestreams
  • rePurpose
  • Silver LEED Certified
  • Certified California Green Business


Reframe|01 is a study of an investigational treatment called luveltamab tazevibulin that directly targets cancer cells with FRα¹

Sutro Biopharma created this study to give morewomen the chance for targeted therapy¹
IN THE PRESS
JOBS
NEWS
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer treatment—antibody-drug conjugates, bispecifics and radiopharmaceuticals—while anti-TIGIT therapies made a bit of a comeback.
With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy.
In 2023, the ADC market exceeded $10 billion, and this momentum is persisting into 2024, as evidenced by several strategic deals and a robust pipeline of candidate drugs.
Under the agreement, Ipsen nabs exclusive global rights for development and commercialization of Sutro Biopharma’s STRO-003, an antibody-drug conjugate which is completing the final stages of preclinical development.
BioSpace’s 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
Astellas Pharma and Sutro Biopharma inked a global collaboration and licensing deal to work to discover and develop novel immunostimulatory antibody-drug conjugates.
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
Sutro Biopharma presented Phase I data at (AACR) showing that its lead compound, STRO-002, not only kills the tumor but also elicits immunogenic cell death.